S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?

Provectus Biopharmaceuticals (PVCT) News Today

$0.15
0.00 (0.00%)
(As of 02/28/2024 ET)
SourceHeadline
finance.yahoo.com logoProvectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call Transcript
finance.yahoo.com - February 23 at 1:52 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
finance.yahoo.com - February 15 at 10:15 AM
globenewswire.com logoProvectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
globenewswire.com - February 15 at 8:00 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Engages irlabs for Investor Relations Services
finance.yahoo.com - February 14 at 8:53 AM
globenewswire.com logoProvectus Biopharmaceuticals Engages irlabs for Investor Relations Services
globenewswire.com - February 14 at 8:00 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
finance.yahoo.com - December 18 at 8:18 AM
morningstar.com logoProvectus Biopharmaceuticals Inc PVCT
morningstar.com - November 19 at 10:00 AM
finanznachrichten.de logoProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
finanznachrichten.de - November 15 at 3:43 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
finance.yahoo.com - November 15 at 10:43 AM
finanznachrichten.de logoProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
finanznachrichten.de - November 13 at 4:23 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
finance.yahoo.com - November 13 at 8:38 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
finance.yahoo.com - November 6 at 8:28 AM
benzinga.com logoProvectus Algae Enters Into Livestock Methane Reduction Space Commissioning First Demonstration Biomanufacturing Plant
benzinga.com - November 2 at 1:41 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
finance.yahoo.com - August 7 at 10:20 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress
finance.yahoo.com - August 1 at 2:36 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas
finance.yahoo.com - June 28 at 9:37 AM
finance.yahoo.com logoPVCT - Provectus Biopharmaceuticals, Inc.
finance.yahoo.com - June 3 at 9:52 AM
chron.com logoProvectus: Q1 Earnings Snapshot
chron.com - May 12 at 9:11 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Publication of Activity of Pharmaceutical-Grade Rose Bengal Sodium (RBS) Against Colistin-Resistant Gram-Negative Bacteria
finance.yahoo.com - April 20 at 10:45 AM
technews.tmcnet.com logoHucu.ai and Provectus expand their relationship into a multi-year partnership
technews.tmcnet.com - April 18 at 5:23 PM
marketwatch.com logoLyophilization Services for Biopharmaceuticals Market Growing Demand and Trends 2023 to 2031
marketwatch.com - March 29 at 11:42 PM
marketwatch.com logoBiopharmaceutical Third Party Logistics (3PL) Market Growth and Competitive Landscape 2023-2029
marketwatch.com - March 27 at 3:45 PM
venturebeat.com logoFormer Estée Lauder Executive Joins Provectus Algae as Cosmetics Advisor Signalling Industry Expansion
venturebeat.com - March 21 at 2:36 PM
forbes.com logoFive Areas Where AI Is Revolutionizing The Biopharmaceutical Industry
forbes.com - March 17 at 8:13 AM
venturebeat.com logoProvectus Algae Receives Strategic Investment from Biotech Leader CJ Bio
venturebeat.com - March 1 at 2:31 PM
nasdaq.com logoRelative Strength Alert For Day One Biopharmaceuticals
nasdaq.com - February 26 at 8:28 PM
marketwatch.com logoBiopharmaceutical Third Party Logistics (3PL) Market Size 2023 Will Touch A New Level In The Upcoming Year 2026
marketwatch.com - February 19 at 3:54 PM
benzinga.com logoShort Volatility Alert: Provectus Biopharm
benzinga.com - January 24 at 12:27 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Releases 2023 Stockholder Letter
finance.yahoo.com - January 9 at 8:38 AM
thestreet.com logoNYSE Places Provectus Listing Status Under Review
thestreet.com - December 31 at 11:10 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
finance.yahoo.com - December 12 at 10:26 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
finance.yahoo.com - December 1 at 7:13 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
finance.yahoo.com - November 10 at 6:32 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient
finance.yahoo.com - November 2 at 7:13 PM
nz.finance.yahoo.com logoProvectus Algae Strengthens R&D Team, Reinforcing Commitment to Delivering Sustainable Synbio Solutions
nz.finance.yahoo.com - October 26 at 1:47 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
finance.yahoo.com - October 25 at 7:43 AM
finance.yahoo.com logoProvectus Biopharmaceuticals, Inc. (PVCT)
finance.yahoo.com - October 20 at 5:42 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing
finance.yahoo.com - September 29 at 11:23 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections
finance.yahoo.com - September 21 at 8:32 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Tennessee Health Science Center to Investigate Pharmaceutical-Grade Rose Bengal as Anti-Fungal and Anti-Oral Bacterial Agent
finance.yahoo.com - August 24 at 1:13 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia
finance.yahoo.com - August 17 at 11:26 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair
finance.yahoo.com - July 19 at 10:47 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress
finance.yahoo.com - June 30 at 6:39 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
finance.yahoo.com - June 23 at 4:18 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Presents Multiple Metabolic Complete Responders from PV-10® Treatment of Early-Stage Metastatic Uveal Melanoma Patients at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 8 at 2:32 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of PH-10 Immuno-Dermatology Agent for Treatment of Inflammatory Dermatoses and Epithelial Diseases
finance.yahoo.com - May 3 at 2:49 PM
seekingalpha.com logoProvectus to get US patent for topical PH-10 to treat certain skin conditions
seekingalpha.com - May 3 at 9:38 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
finance.yahoo.com - April 27 at 2:11 PM
seekingalpha.com logoProvectus to get US patent for PV-10 to treat hematologic diseases
seekingalpha.com - April 26 at 9:56 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology
finance.yahoo.com - April 26 at 9:56 AM
Get Provectus Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter.



PVCT Media Mentions By Week

PVCT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PVCT
News Sentiment

1.66

0.68

Average
Medical
News Sentiment

PVCT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PVCT Articles
This Week

2

0

PVCT Articles
Average Week

Get Provectus Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (OTCMKTS:PVCT) was last updated on 2/29/2024 by MarketBeat.com Staff